A Phase 3 interventional study of Cabozantinib and Cabozantinib in Hepatocellular Carcinoma, sponsored by Exelixis. Active, not recruiting at 245 sites in 34 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-11.
Sponsored by Exelixis · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies testing cabozantinib in Carcinoma, Hepatocellular — 7 open to participants now, 11 under way, 2 of them phase 3. cabozantinib · Carcinoma, Hepatocellular.
Among the 27 studies testing cabozantinib in Carcinoma, Hepatocellular, this one is the 3rd largest by enrollment, is one of 4 that started in 2018, is one of 3 in phase 3, reaches primary completion later than 1 of the 10 other live ones, and was the 9th registered.
3,651 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,062 are open to participants now.
Browse Carcinoma, Hepatocellular studies →7 of the 27 studies testing cabozantinib in Carcinoma, Hepatocellular are open now, in 4 countries. Recruiting first, the newest first:
University Health Network, Toronto · Sites in Canada
Ages 18+
University of California, Irvine · Sites in United States
Ages 18+
Humanity & Health Medical Group Limited · Sites in Hong Kong
Ages 18+
Anwaar Saeed · Sites in United States
Ages 18+
Exelixis · Sites in United States
By country, each count listing its studies:
cabozantinib: first FDA approval 2012 (COMETRIQ), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 737 Carcinoma, Hepatocellular studies recruiting now, 382 (52%) set no upper age limit and 249 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, cabozantinib is the treatment under test here. Read study by study →
27 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 20 · Phase 3 3 · Phase 4 1
First in 2009; this study’s year is marked. 4 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 837 is above the median of 54 across 2,619 interventional studies indexed under Carcinoma, Hepatocellular.
Median enrollment 35 across the 27 interventional studies. Of the 12 that completed or were terminated, 7 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 27 have an industry lead sponsor. The 10 most frequent:
Exelixis is the lead sponsor of 57 studies on the registry; 11 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Exelixis has 6 studies filed under Carcinoma, Hepatocellular — fewer than ten, so there is no comparison to draw.
1 of the studies testing cabozantinib in Carcinoma, Hepatocellular that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04472767University of California, IrvineCabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatocellular Carcinoma | 2027-01-31 |
Add it to your calendar (.ics) → With an account.
Among the 27 studies testing cabozantinib in Carcinoma, Hepatocellular, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This Phase 3 study evaluates the safety and efficacy of cabozantinib in combination with atezolizumab versus the standard of care sorafenib in adults with advanced hepatocellular carcinoma (HCC) who have not received previous systemic anticancer therapy. A single-agent cabozantinib arm will be enrolled in which participants receive single agent cabozantinib in order to determine its contribution to the overall safety and efficacy of the combination with atezolizumab.
This is a multicenter, randomized, open-label, controlled Phase 3 trial of cabozantinib in combination with atezolizumab versus sorafenib in adults with advanced HCC who have not received previous systemic anticancer therapy in the advanced HCC setting. The primary objective of this study is to evaluate the effect of cabozantinib in combination with atezolizumab on the duration of progression-free survival (PFS) and duration of overall survival (OS) versus sorafenib. The secondary objective is to evaluate the activity of single-agent cabozantinib compared with sorafenib in this patient population.
Key Inclusion Criteria:
Key Exclusion Criteria:
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with advanced HCC will receive cabozantinib 40 milligrams (mg) oral, once daily (qd) + atezolizumab 1200 mg infusion, once every 3 weeks (q3w)
Drug: Cabozantinib · Drug: Atezolizumab
Participants with advanced HCC will receive sorafenib 400 mg twice a day (bid)
Drug: Sorafenib
Participants with advanced HCC will receive cabozantinib 60 mg qd
Drug: Cabozantinib
Supplied as 20-mg tablets; administered orally daily at 40 mg
Also known as: XL184, Cabometyx®
Supplied as 60-mg tablets; administered orally once daily at 60 mg
Also known as: XL184, Cabometyx®
Supplied as 200-mg tablets; administered orally twice daily at 400 mg
Also known as: Nexavar®
Supplied as 1200 mg/20 mL (60 mg/mL) in sing-dose vials; administered as an intravenous (IV) infusion q3w
Also known as: Tecentriq®
Progression Free Survival (PFS) for the Experimental Arm Versus the Control Arm in the PFS Intent to Treat (PITT) Population
PFS was defined as the time from randomization to the earlier of either the date of radiographic progression defined as a 20% increase in the sum of the longest diameters of target lesions, or the unequivocal appearance of new lesions, or progression of non-target disease per Blinded Independent Radiology Committee (BIRC) or the date of death due to any cause per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
Time frame: From the date of first participant randomization up to 28 months
Overall Survival (OS) for the Experimental Arm Versus the Control Arm in the ITT Population
OS was defined as the time from randomization to death due to any cause.
Time frame: From the date of first participant randomization up to 36 months
PFS for the Single-Agent Cabozantinib Arm Versus the Control Arm in the ITT Population
PFS was defined as the time from randomization to the earlier of either the date of radiographic progression per BIRC or the date of death due to any cause per RECIST version 1.1.
Time frame: From the date of first participant randomization up to 28 months
| Milestone | Experimental Arm: Cabozantinib + Atezolizumab | Single-Agent Cabozantinib | Control Arm: Sorafenib |
|---|---|---|---|
| Started | 432 | 188 | 217 |
| Received at least 1 dose of study drug | 429 | 188 | 207 |
| Completed | 0 | 0 | 0 |
| Not completed | 432 | 188 | 217 |
| Withdrew: Did not receive any study treatment | 3 | 0 | 10 |
| Withdrew: Radiographic progression | 204 | 92 | 115 |
| Withdrew: Adverse event | 140 | 60 | 51 |
| Withdrew: Lack of efficacy | 12 | 6 | 6 |
| Withdrew: Withdrawal by subject | 26 | 23 | 24 |
| Withdrew: Sponsor decision, | 41 | 5 | 7 |
| Withdrew: Lost to follow-up | 1 | 0 | 2 |
| Withdrew: Protocol violation | 0 | 0 | 2 |
| Withdrew: Other than specified | 5 | 2 | 0 |
PFS was defined as the time from randomization to the earlier of either the date of radiographic progression defined as a 20% increase in the sum of the longest diameters of target lesions, or the unequivocal appearance of new lesions, or progression of non-target disease per Blinded Independent Radiology Committee (BIRC) or the date of death due to any cause per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
| months | Experimental Arm: Cabozantinib + Atezolizumab | Control Arm: Sorafenib |
|---|---|---|
| Progression Free Survival (PFS) for the Experimental Arm Versus the Control Arm in the PFS Intent to Treat (PITT) Population | 6.80 (5.55 to 8.34) | 4.21 (2.79 to 7.03) |
OS was defined as the time from randomization to death due to any cause.
| months | Experimental Arm: Cabozantinib + Atezolizumab | Control Arm: Sorafenib |
|---|---|---|
| Overall Survival (OS) for the Experimental Arm Versus the Control Arm in the ITT Population | 16.46 (14.46 to 18.56) | 15.51 (12.19 to 19.98) |
PFS was defined as the time from randomization to the earlier of either the date of radiographic progression per BIRC or the date of death due to any cause per RECIST version 1.1.
| months | Single-Agent Cabozantinib | Control Arm: Sorafenib |
|---|---|---|
| PFS for the Single-Agent Cabozantinib Arm Versus the Control Arm in the ITT Population | 5.82 (5.42 to 8.18) | 4.27 (2.86 to 6.11) |
Collected over Up to 39 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Experimental Arm: Cabozantinib + Atezolizumab | 307/429 (71.6%) | 226/429 (52.7%) | 414/429 (96.5%) |
| Single-Agent Cabozantinib | 135/188 (71.8%) | 88/188 (46.8%) | 182/188 (96.8%) |
| Control Arm: Sorafenib | 141/207 (68.1%) | 85/207 (41.1%) | 202/207 (97.6%) |
| Event | Experimental Arm: Cabozantinib + Atezolizumab | Single-Agent Cabozantinib | Control Arm: Sorafenib |
|---|---|---|---|
| Hepatocellular carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 38/429 | 26/188 | 18/207 |
| Hepatic encephalopathyNervous system disorders | 12/429 | 7/188 | 1/207 |
| AscitesGastrointestinal disorders | 15/429 | 3/188 | 3/207 |
| COVID-19Infections and infestations | 12/429 | 3/188 | 2/207 |
| PyrexiaGeneral disorders | 11/429 | 1/188 | 1/207 |
| SepsisInfections and infestations | 11/429 | 4/188 | 2/207 |
| Abdominal painGastrointestinal disorders | 8/429 | 4/188 | 4/207 |
| DiarrhoeaGastrointestinal disorders | 9/429 | 4/188 | 0/207 |
| Hepatic failureHepatobiliary disorders | 8/429 | 4/188 | 2/207 |
| PneumoniaInfections and infestations | 7/429 | 4/188 | 3/207 |
| Event | Experimental Arm: Cabozantinib + Atezolizumab | Single-Agent Cabozantinib | Control Arm: Sorafenib |
|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 215/429 | 102/188 | 98/207 |
| Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders | 185/429 | 82/188 | 92/207 |
| Decreased appetiteMetabolism and nutrition disorders | 128/429 | 81/188 | 43/207 |
| Aspartate aminotransferase increasedInvestigations | 138/429 | 61/188 | 30/207 |
| FatigueGeneral disorders | 113/429 | 60/188 | 36/207 |
| Alanine aminotransferase increasedInvestigations | 134/429 | 56/188 | 24/207 |
| HypertensionVascular disorders | 106/429 | 56/188 | 39/207 |
| Weight decreasedInvestigations | 82/429 | 48/188 | 33/207 |
| HypothyroidismEndocrine disorders | 93/429 | 36/188 | 9/207 |
| NauseaGastrointestinal disorders | 70/429 | 40/188 | 30/207 |
The Intent-to-Treat (ITT) population consisted of all participants who were randomized to any of the three study treatment arms, regardless of whether they received any study treatment.
| Age, Categorical(Participants) | Experimental Arm: Cabozantinib + Atezolizumab | Single-Agent Cabozantinib | Control Arm: Sorafenib | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 234 | 97 | 112 | 443 |
| >=65 years | 198 | 91 | 105 | 394 |
| Sex: Female, Male(Participants) | Experimental Arm: Cabozantinib + Atezolizumab | Single-Agent Cabozantinib | Control Arm: Sorafenib | Total |
|---|---|---|---|---|
| Female | 72 | 30 | 31 | 133 |
| Male | 360 | 158 | 186 | 704 |
| Race/Ethnicity, Customized(Participants) | Experimental Arm: Cabozantinib + Atezolizumab | Single-Agent Cabozantinib | Control Arm: Sorafenib | Total |
|---|---|---|---|---|
| Hispanic or Latino | 42 | 21 | 15 | 78 |
| Not Hispanic or Latino | 352 | 158 | 183 | 693 |
| Not Reported | 38 | 9 | 19 | 66 |
| Race/Ethnicity, Customized(Participants) | Experimental Arm: Cabozantinib + Atezolizumab | Single-Agent Cabozantinib | Control Arm: Sorafenib | Total |
|---|---|---|---|---|
| Asian | 127 | 64 | 72 | 263 |
| Black/African American | 8 | 5 | 1 | 14 |
| White | 217 | 95 | 111 | 423 |
| Other than specified | 80 | 24 | 33 | 137 |
Showing the first 100 of 245 sites across 34 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jun 2018 to primary completion in Nov 2021, 41 months.
Results were first posted in Dec 2025, 4 years after primary completion. A results delay was requested in Mar 2022.
Of 52 industry-sponsored phase 3 interventional studies under Carcinoma, Hepatocellular, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 63. This study's 41 months is below that.
Counting every sponsor, half of 138 studies reached it within 56 months; a quarter within 43 and three quarters within 83.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Cabozantinib · Atezolizumab